Medical Condition

glioma

Total Trials

23

Recruiting Now

23

Trial Phases

EARLY_Phase 1, Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for glioma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — glioma Clinical Trials

How many clinical trials are currently recruiting for glioma?

ClinicalMetric currently tracks 23 actively recruiting clinical trials for glioma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 23. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for glioma?

glioma research spans Phase 1 (6 trials), Phase 2 (4 trials), Phase 3 (3 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a glioma clinical trial?

Eligibility criteria for glioma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Phase 4

Top Sponsors

Mayo Clinic 2 trials

M.D. Anderson Cancer Center 2 trials

Massachusetts General Hospital 1 trial

Henry Ford Health System 1 trial

Baptist Health South Florida 1 trial

glioma

Frequently Asked Questions — glioma Clinical Trials

Recruiting Clinical Trials

Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

ASCENT Intervention for Brain Tumor Patients

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

Reducing Cognitive Impairment in Glioma with Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training

The Role of B7-H4 in Tumor Vaccine

Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures

Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients